Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance

Sahitya K. Denduluri\textsuperscript{a,b}, Olumuyiwa Idowu\textsuperscript{a,b}, Zhongliang Wang\textsuperscript{b,c}, Zhan Liao\textsuperscript{b,d}, Zhengjian Yan\textsuperscript{b,c}, Maryam K. Mohammed\textsuperscript{a,b}, Jixing Ye\textsuperscript{b,e}, Qiang Wei\textsuperscript{b,c}, Jing Wang\textsuperscript{b,c}, Lianggong Zhao\textsuperscript{b,f}, and Hue H. Luu\textsuperscript{b,*}

\textsuperscript{a} The University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
\textsuperscript{b} Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, 5841 South Maryland Avenue, MC 3079, Chicago, IL 60637, USA
\textsuperscript{c} Ministry of Education Key Laboratory of Diagnostic Medicine, The Affiliated Hospitals of Chongqing Medical University, Chongqing 400016, China
\textsuperscript{d} Department of Orthopaedic Surgery, Xiang-Ya Hospital of Central South University, Changsha 410008, China
\textsuperscript{e} School of Bioengineering, Chongqing University, Chongqing, China
\textsuperscript{f} Department of Orthopaedic Surgery, the Second Affiliated Hospital of Lanzhou University, Lanzhou, Gansu 730000, China

Abstract

One of the greatest obstacles to current cancer treatment efforts is the development of drug resistance by tumors. Despite recent advances in diagnostic practices and surgical interventions, many neoplasms demonstrate poor response to adjuvant or neoadjuvant radiation and chemotherapy. As a result, the prognosis for many patients afflicted with these aggressive cancers remains bleak. The insulin-like growth factor (IGF) signaling axis has been shown to play critical role in the development and progression of various tumors. Many basic science and translational studies have shown that IGF pathway modulators can have promising effects when used to treat various malignancies. There also exists a substantial body of recent evidence implicating IGF signaling dysregulation in the dwindling response of tumors to current standard-of-care therapy. By better understanding both the IGF-dependent and -independent mechanisms by which pathway members can influence drug sensitivity, we can eventually aim to use modulators of IGF signaling to augment the effects of current therapy. This review summarizes and synthesizes numerous recent investigations looking at the role of the IGF pathway in drug resistance. We offer a brief overview of IGF signaling and its general role in neoplasia, and then delve into detail about the many types of human cancer that have been shown to have IGF pathway involvement in resistance
and/or sensitization to therapy. Ultimately, our hope is that such a compilation of evidence will compel investigators to carry out much needed studies looking at combination treatment with IGF signaling modulators to overcome current therapy resistance.

**Keywords**

Cancer; Insulin-like growth factor; Resistance; Therapy; Tumorigenesis

---

**Introduction**

The insulin-like growth factor (IGF) signaling axis is critical to the growth, development, and maintenance of many tissues within the human body.\(^1\) It is particularly important during neonatal and pubertal growth, and essentially carries out its effects by simulating cell proliferation and interrupting programmed cell death.\(^1,2\) The IGF system is comprised of two ligands, IGF-1 and IGF-2, which exhibit their effects through binding to IGF-1R (primarily), IGF-2R, and the insulin receptor (IR), all belonging to the tyrosine kinase receptor family.\(^1\)

Upon binding the IGF ligand, IGF-1R is activated through autophosphorylation, and subsequently phosphorylates insulin receptor substrate 1 (IRS-1).\(^2\) Activated phosphoinositide 3-kinase (PI3K) then leads to increased phosphatidylinositol 3,4,5-trisphosphate (PIP3), which results in the activation of the critical protein AKT/PKB (AKT for short) through phosphorylation.\(^3\) AKT then performs a variety of functions, such as releasing the anti-apoptotic protein Bcl-2 from Bad, activating protein synthesis through mTOR, and promoting glucose metabolism by inhibiting GSK-3\(\beta\).\(^3,4\) This is commonly referred to as the PI3K/AKT pathway of IGF-1R signaling and is ultimately responsible for preventing cell death (Fig. 1).\(^5\)

In parallel, IGF-1R signaling also promotes cell differentiation proliferation via the Ras/MAPK pathway (Fig. 1).\(^3\) IGF-1R activates the IRS protein SHC, which then stimulates Raf through the GTPase Ras. Raf then triggers a kinase cascade eventually resulting in the activation of mitogen-activated protein kinases (MAPKs), ERK1 and ERK2. These MAPKs go on to phosphorylate and activate several targets, notably the transcription factor ELK1 which promotes gene expression and therefore cell growth.\(^3,6,7\)

The activity of the IGF ligands and receptors is modulated in a complex fashion by six IGF binding proteins (IGFBPs), named IGFBP-1 through IGFBP-6, respectively. The IGFBPs are usually bound directly to IGF-1 (or IGF-2) in extracellular fluids, serving to mediate the half-life and localized availability of the ligands in circulation.\(^8\) Furthermore, extensive evidence has recently elucidated that the IGFBPs have many IGF-independent actions. By associating directly with many extracellular and cell-surface markers, these binding proteins are able to cause a variety of unique effects involving growth and differentiation.\(^8\)

Taken as a whole, the IGF signaling axis has vast implications for cellular proliferation, apoptosis, and interactions with the microenvironment. Though these processes are critical for normal development and maintenance of tissues, it has also become increasingly evident
that dysregulation of this pathway contributes significantly to abnormal growth and disease states.

**IGF signaling in cancer and the development of drug resistance**

Numerous cancers have been shown to be associated with aberrant IGF signaling, including colon cancer, prostate cancer, pancreatic cancer, melanoma, osteosarcoma, and childhood malignancies, among many others. Numerous \textit{in vitro}, \textit{in vivo}, and clinical studies have shown that increased IGF-1R activity is implicated in cancer cell proliferation, migration, and invasion. \textsuperscript{9,10} IGF ligand appears to be delivered not only from distant sources (i.e. endocrine signaling), but also through paracrine/autocrine signaling in more aggressive tumors. \textsuperscript{10} In addition, increased serum levels of IGF-1 have been observed in cancers of the lung, colon, prostate, and breast. \textsuperscript{11–14} Many other IGF pathway members are also thought to play a role in malignancies. From increased circulating levels of IGF-2 in colorectal cancer to suppressed activity of IGFBP-5 in osteosarcoma, it is clear that the IGF axis serves as an important lens to better understand and address the underlying mechanisms of neoplasia. \textsuperscript{15–17} In fact, several IGF signaling modulators have undergone significant basic science and translational investigations with promising results; currently, monoclonal antibodies to IGF-1R are undergoing clinical trials. \textsuperscript{18} However, it has become clear that the IGF axis is part of a much larger network of cellular signaling that ultimately results in the highly proliferative and invasive cancer phenotypes. \textsuperscript{19}

Current non-surgical forms of cancer treatment are largely limited by severe systemic side effects and acquired resistance, resulting in increased morbidity and decreased survival. Of the many processes that are thought to play a role in the resistance of neoplasms to radiation or chemo-therapy, the IGF signaling axis has been recurrently deemed as a culprit. \textsuperscript{20} Here, we review recent literature implicating IGF signaling in resistance to therapy among various types of human cancer. With a better grasp of the underlying mechanisms, we can one day hope to augment the efficacy of existing cancer therapy using modulators of the IGF signaling axis.

**Breast cancer**

Breast cancer is one of the most prevalent diseases in the world, and considered to be the most invasive cancer in women. Though there have been significant technological and public health improvements leading to early detection and surgical removal of tumors, disease-free survival remains limited due to drug resistance. \textsuperscript{21} Of the various mechanisms that are thought to contribute to this, IGF signaling has recently been implicated as a crucial factor.

In estrogen receptor positive (ER+) breast cancer, there appears to be a link between IGF-1R and progression of disease despite anti-estrogen therapy. In fact, IGF-1R is upregulated in cancer cells that are resistant to tamoxifen, an estrogen antagonist in breast tissue. \textsuperscript{22} This is thought to be due to crosstalk between IGF-1R and ER, as well as MAPK/ERK and PI3K/AKT signaling downstream of IGF signaling. \textsuperscript{23,24} One study looked at ER+ breast cancer cells resistant to long-term estrogen deprivation, showing that AKT inhibition led to compensatory upregulation of IGF-1R/IR and IGF ligands, but that simultaneous blockade...
of IGF-1R/IR enhanced the anti-tumor effects of AKT inhibition. Furthermore, variations in IGF-1R structure and function correlate with anti-estrogen resistance. In a study of 222 British patients with ER+ invasive breast cancer treated with tamoxifen, a polymorphism of the IGF-1R gene was found to have significantly increased risk for tumor progression (hazard ratio [HR] 2.04) and death (HR 1.84). Other polymorphisms were also found to be significantly associated with tumor size and lymph node involvement. Finally, the activity of IGFBPs is also implicated, but in an IGF-independent manner. For example, IGFBP-3 appears to sensitize ER+ breast cancer cells to the anti-estrogen fulvestrant by inhibiting anti-apoptotic effects of GRP78, a binding partner of the caspase 7 complex.

Another prevalent form of breast cancer is HER2 receptor positive (HER2+), and drugs that work by targeting this marker have also met with significant tumor resistance. Trastuzumab (Herceptin) is a monoclonal antibody to HER2 that is commonly used in therapy, but limited drug efficacy appears to be, in large part, due to IGF signaling. In models of breast cancer cells that overexpress HER2, trastuzumab activity is disrupted by increased expression of IGF-1R. Furthermore, upregulation of IGF-1R by epigenetic silencing of microRNA 375 partially leads to a trastuzumab-resistant phenotype, while overexpression of microRNA 375 restores sensitivity of HER2+ cells to the drug. Immunohistochemistry supports that overexpression of IGF-1R and epidermal growth factor 1-receptor (EGFR), and/or dysregulation of the downstream PI3K/AKT pathway can also confer this trastuzumab resistance in a subset of patients found to have metastases.

It is clear that IGF signaling has significant implications for treatment and survival of breast cancer patients. This has led many to believe that co-targeting IGF-1R and well-known breast cancer cell receptors (e.g. ER, HER2) may circumvent drug resistance. However, several investigations indicate that the solution may not be so straightforward. A recent study using estrogen-resistant ER+ breast cancer cells demonstrated that dual treatment with fulvestrant and dasatinib, a nonspecific tyrosine kinase inhibitor, had superior outcomes when compared to combination fulvestrant and IGF-1R monoclonal antibody therapy. This may be due to fact that tyrosine-kinases in general are upregulated in endocrine therapy-resistant breast tumors. Moreover, another study showed that ER+ cancer cells selected for tamoxifen resistance in vitro may actually have decreased IGF-1R expression and therefore less responsiveness to monoclonal antibodies directed against just this receptor. The incongruence of these results with those of studies mentioned previously in this review may ultimately be due to methodology, but highlights the notion that growth factor and hormone signaling in neoplasms is incredibly complex. Nonetheless, the IGF signaling axis remains an intriguing entity in breast cancer and drug resistance.

**Ovarian cancer**

Ovarian cancer is one of the deadliest diseases in women, with diagnosis usually made after the onset of symptoms and when metastases are already present. In addition, significant drug resistance has been reported to current chemotherapy regimens, which is particularly devastating to those patients who may not be candidates for surgical intervention. Similar to its implications in breast cancer, the IGF signaling pathway appears to also play a role in ovarian cancer drug resistance. In A2780 ovarian carcinoma cells treated with either
cisplatin or cisplatin and taxol in vitro, early stages of drug resistance are correlated with upregulation of IGF-1R. Furthermore, primary tumors harvested from patients after 3–4 cycles of platinum-taxol treatment also demonstrate increased IGF-1R expression. A gene microarray study of 28 patients with high-grade serous ovarian cancer demonstrated that samples relatively resistant to platinum chemotherapy showed enrichment of genes involving IGF1/PI3K/NFκB/ERK signaling when compared to those tumors remaining sensitive to treatment. This finding, replicated in several studies, is thought to be the result of two distinct mechanisms beyond just IGF-1R upregulation, including loss of the tumor suppressor PTEN and IGF-2 overexpression.

Interestingly, IGF-2 is thought to be more closely associated with ovarian cancer drug resistance, despite being less prevalent than IGF-1 in signaling. An analysis of serous ovarian cancer patients using The Cancer Genome Atlas demonstrated that higher IGF-2 mRNA expression was correlated with indicators of drug resistance, including a shorter time to disease progression and death. In addition, transient knockdown of IGF-2 using short-hairpin RNA restores taxol sensitivity in a xenograft model of serous papillary ovarian carcinoma. Other studies have also demonstrated efficacy by inhibiting this pathway. Ganitumab, a human monoclonal antibody to IGF-1R, can augment the response to platinum-based chemotherapy by inhibiting IGF-2-dependent ovarian cancer growth. However, blockade of IGF-1R does not seem to counteract taxol resistance. This may be explained by the fact that cisplatin and taxol resistance may not arise from the same signaling mechanisms, though members of the IGF pathway appear to be critically involved in both cases. As in breast cancer, the IGF signaling axis represents a target for much needed effective therapy in ovarian cancer.

**Prostate cancer**

Prostate cancer remains one of the leading concerns in men’s health, accounting for about 15% of all new cancer cases in the U.S. every year. When distant metastases are present, the 5-year relative survival is only 28% when compared to localized disease, making pharmacologic therapy all the more critical in these patients. In patients with disseminated disease, androgen deprivation therapy (ADT) is the standard approach and can be accomplished either surgically through bilateral orchiectomy or medically using a continuous gonadotropin releasing hormone (GnRH) agonist. Tumors that respond to this therapy are referred to as castration sensitive, though there are an alarming number of cases that become castration resistant (or androgen independent [AI]) [need citation].

As in other neoplasms, IGF-1R has been extensively implicated in the progression of prostate cancer, particularly through contributing to the development of AI disease. There has been considerable research into the interactions between IGF-1R and the androgen receptor (AR). Normally, AR binds to an androgen ligand and is subsequently translocated from the cytoplasm to the nucleus of cells, where it serves as a transcription factor and promotes tissue growth. In the absence of androgen ligand, as is the case with ADT in prostate cancer, an inactive AR remains in the cytosol. However, it appears that in certain cases IGF signaling actually can actually drive translocation of AR into the nucleus, even in the absence of androgen. This presents a potential mechanism by which prostate cancer
can progress to AI disease, especially if IGF signaling is upregulated. Furthermore, studies show that inhibiting IGF-1R using an antibody can prevent this transactivation of AR, establishing a potential therapy for prostate cancer progression despite castration.\textsuperscript{42}

It appears that IGFBPs also have significant roles in driving prostate cancer development. IGFBP-1 is known to upregulate IGF-1 activity by modulating serum concentrations and tissue delivery of the ligand. Thus, it follows that in patients with metastatic disease undergoing ADT, increased levels of IGFBP-1 are associated with a shorter interval to castration resistance, and consequently, decreased survival.\textsuperscript{45} In vivo studies also show that deleting IGFBP-1 in mice actually decreases growth of prostate tumors, perhaps by activating a5b1 integrin in an IGF- independent manner.\textsuperscript{46,47} There has also been significant research looking at the link between insulin-resistance/ diabetes and prostate cancer, with IGFBP-2 being recently implicated in this phenomenon. In docetaxel-treated prostate cancer cell lines, hyperglycemia significantly reduces drug-induced apoptosis through glucose-mediated upregulation of IGFBP-2. Knocking out IGFBP-2, on the other hand, reverses the survival effect caused by hyper-glycemia.\textsuperscript{48} Finally, IGFBP-related proteins (IGFBP-rPs), similar in structure and function to IGFBPs but with weaker affinity for IGF ligands, can play a role in reversing prostate cancer resistance. Restoring IGFBP-rP1 activity has been found to increase both chemosensitivity to docetaxel and radiosensitivity of prostate cancer cells \textit{in vitro}.\textsuperscript{49} Ultimately, it is evident that a better understanding of various members of the IGF signaling axis can help lead to more effective treatment of drug-resistant prostate cancer.

\section*{Lung cancer}

Lung cancer is one of the most devastating human diseases, accounting for more than a quarter of all cancer deaths.\textsuperscript{50} At the time of diagnosis, many patients do not qualify for surgical intervention, and those who are able to have the primary tumor resected still remain susceptible to disease progression and distant metastasis due to drug resistance.\textsuperscript{51} Again, the IGF signaling pathway appears to be implicated in this resistance, and targeting it presents a potential approach to lung cancer treatment moving forward. Gefitinib, an epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitor (TKI), is one of the most commonly used drugs for non-small cell lung cancer (NSCLC). Many studies have demonstrated decreased response of NSCLC tumors and cell lines to gefitinib, and IGF-1R appears to be a marker associated with this resistance. Essentially, it appears as though IGF signaling is upregulated as a means of compensating for the EGFR blockade, in part contributing to a drug-resistant phenotype.

One study found that the activity of IGF-1R predicts resistance of NSCLC to gefitinib, though it may not actually play a role in development of drug resistance itself. That is, cell lines that were already resistant to gefitinib were found to have increased total-IGF-1R and phosphorylated-IGF-1R expression, but overexpression of IGF-1R did not confer resistance to gefitinib-sensitive cells.\textsuperscript{52} Another study looking at IGF-1R expression using immunohistochemistry did not find any association between IGF-1R activity and clinical outcomes of gefitinib-treated NSCLC.\textsuperscript{53} These disparate conclusions may ultimately be attributed to the characteristics of patient samples used in these studies, as tumor
microenvironment appears to contribute heavily to the molecular properties of cancer cells. For example, in NSCLC with an activating mutation of EGFR, IGF-1R activity promotes resistances to gefitinib in lung cancer stem cells (CSCs) under hypoxic conditions. Furthermore, inhibiting IGF-1R actually decreases the population of gefitinib-resistant CSCs in the setting of hypoxia. Thus, it is possible that IGF-1R may indeed drive NSCLC tumor resistance to drugs such as gefitinib, but perhaps only in specific cell lines and under particular micro-environmental conditions.

Analogous patterns of IGF-1R overexpression in NSCLC drug resistance have been demonstrated with erlotinib, another EGFR-TKI. Furthermore, in tumors that preferentially respond to erlotinib therapy due to an EGFR-activating mutation in exon 19, crosstalk between IGF-1R and epithelial-mesenchymal transition (EMT) signaling can rapidly confer drug resistance. In fact, the median interval between initiation of EGFR-TKI therapy and acquired resistance is only 6–12 months in patients afflicted by tumors with this common mutation. Therefore, there is a significant need to block IGF-1R/EMT crosstalk in patients that are identified to have this mutation, especially since their initial response to therapy can be so pronounced.

Regardless of the mechanisms by which EGFR-TKI resistance arises, it seems that IGF-1R inhibition can play a role in re-sensitizing tumors to drugs. AG1024, which prevents autophosphorylation of IGF-1R, synergizes with gefitinib to produce pro-apoptotic and anti-proliferative effects in vitro in previously gefitinib-resistant NSCLC cells. In mutant KRAS lung adenocarcinoma, IGF's downstream PI3K/AKT signaling is thought to be involved with both this gefitinib resistance and re-sensitization by interacting with the anti-apoptotic Ku70 and pro-apoptotic BAX proteins.

The IGFBPs have also been found to play a role in lung cancer resistance to chemotherapy. Apart from binding to ligands and mediating direct IGF-1R signaling, the IGFBPs are known to trigger various independent effects as well. For example, IGFBP-2 directly interacts with integrins and the extracellular matrix to stimulate growth. IGFBP-2 appears to be causally associated with NSCLC resistance to dasatinib, a BCR-ABL and SRC family TKI. Further more, focal adhesion kinase (FAK), which is downstream of IGFBP-2 and integrin binding, is correlated with increased levels of IGFBP-2 and contributes to the dasatinib-resistant phenotype. Both in vitro and in vivo, dual inhibition of IGFBP-2 and FAK reverses NSCLC resistance by restoring apoptotic sensitivity to dasatinib. It stands to reason that both IGFBP-2 and FAK may be used as biomarkers and therapeutic targets in patients with NSCLC to predict and augment response to dasatinib.

Unlike IGFBP-2, IGFBP-3 appears to be inversely correlated with TKI resistance. NSCLC lines with acquired resistance to gefitinib or erlotinib demonstrate decreased secretion of IGFBP-3 in vitro. However, upon evaluating the serum of 20 patients, there was no observed difference in IGFBP-3 levels before and after developing resistance to EGFR-TKI. These disparate conclusions may be explained by understanding that IGFBP-3 levels are primarily maintained by hepatic cells. That is, IGFBP-3 may serve as a marker of resistance on a cellular level in lung cancer, but this difference is washed out on an organismal level because the tumor's contribution to serum levels is proportionally insignificant. Furthermore,
it seems that the protein may not actually be involved in the pathophysiology of EGFR-TKI resistance. Adenoviral expression or small interfering RNA (siRNA) suppression of IGFBP-3 does not alter the response of NSCLC to these drugs.\textsuperscript{65} Conversely, IGFBP-3 shows some promise in lung cancer that has become resistant to cisplatin (CDDP) therapy. In cells treated with CDDP, promoter methylation decreases expression of IGFBP-3, thereby driving signaling activity of the IGF-1R/PI3K/AKT pathway and inducing resistance.\textsuperscript{67} Treating H640 NSCLC cells with recombinant human IGFBP-3 or IGF-1R-inhibiting siRNA can confer sensitivity to cisplatin, further demonstrating that both of these members may belong to the same drug resistance pathway.\textsuperscript{68}

Finally, IGFBP-7 is thought to be a tumor suppressor, downstream of p53, with implications for treating drug-resistant lung cancer.\textsuperscript{69} MAP kinase phosphatase 3 (MKP3) has been found to reduce expression of IGFBP-7, driving NSCLC resistance to cisplatin therapy. Furthermore, MKP3 knockdown increases the transcriptional level of IGFBP-7, which presents a promising approach for sensitizing tumors to cisplatin.\textsuperscript{70} Ultimately, the IGF signaling axis presents numerous opportunities for researchers to better understand and attempt to overcome drug resistance in one of deadliest forms of cancer.

**Central Nervous System (CNS) tumors**

Glioma comprises about 30\% of all CNS tumors, with a particularly poor prognosis when diagnosed in the brain.\textsuperscript{71} Surgical resection is often not an option for many patients, who rely immensely on radio- and chemotherapy. In these cases, tumors acquire resistance within just a short interval after beginning therapy.\textsuperscript{72} In terms of radiation, cancer stem cells have been found to play a critical role in tumor progression despite aggressive treatment. Not surprisingly, IGF-1R signaling seems to be involved in glioma stem cells’ (GSCs) ability to adapt to repeated irradiation. One study showed that radiation exposure caused an upregulation of both IGF1 secretion and IGF-1R expression, leading to downstream AKT survival signaling in GSCs. Furthermore, treating radioresistant cells with an IGF-1R inhibitor markedly increases sensitivity to radiation.\textsuperscript{73}

With regards to chemotherapy and glioma, members of the IGF axis are again thought to contribute to resistance mechanisms. In GSCs, there appears to exist cooperative signaling between the Hedgehog (HH) pathway and the IGF axis that promotes resistance to temozolamide. GLI1, a transcription factor downstream of HH that targets insulin receptor substrate 1 (IRS-1), allows for activation of MAPK by IGF-1 signaling, leading to cell proliferation. Suppressing GLI1 decreases IGF-1-dependent proliferation, invasion, and angiogenesis by increasing GSC response to temozolamide.\textsuperscript{74} Independent of HH, IGF-1-induced activation of PI3K appears to protect U251 glioma cells from tamoxifen-induced apoptosis, which can be partially overcome by combination treatment with a specific PI3K inhibitor (LY294002) or PI3K subunit P85 siRNA. Furthermore, the effects of LY294002 appear to be mediated through activation (or dephosphorylation) of GSK3, which inhibits gene transcription by β-catenin.\textsuperscript{75} Despite this compelling evidence that IGF signaling contributes to drug resistance, other studies have muddied the waters. A recent investigation demonstrated that the transcription factor Wilms’ tumor 1 (WT1) increases the survival of glioblastoma cells in the presence of cisplatin and carbustine. However, though silencing

*Genes Dis.* Author manuscript; available in PMC 2015 May 14.
WT1 did increase sensitivity to the drugs, there was increased IGF-1R expression as a result. These disparate conclusions regarding IGF activity in glioma may be attributed to the complex and seemingly independent mechanisms by which resistance arises for different classes of drugs.

IGFBP-2, which is overexpressed in nearly 80% of all glioblastoma multiforme cases, appears to induce chemo-resistance through an IGF-independent mechanism. Exogenous IGFBP-2 promotes proliferation and invasion of several glioma lines, even in the presence of temozolomide. Immunofluorescence staining and in vitro knockdown models show that this effect is mediated through activation of integrin β1 and downstream phosphorylation and nuclear translocation of ERK. Therefore, IGFBP-2 presents yet another promising target for overcoming drug resistance that may prove successful where direct IGF signaling inhibitors fall short. Ultimately, it will be necessary to identify reliable markers so as to determine not only the primary mechanism by which resistance arises, but also to predict the efficacy of IGF signaling inhibitors in novel combination treatment regimens for glioma.

Gastrointestinal cancers

Gastrointestinal (GI) neoplasms represent a significant proportion of all new cancers diagnosed yearly, with prognosis ranging from good to dismal based on the organs involved and the extent of invasion. Gastric cancer represents a form of malignancy with relatively poor outcomes, in large part due to limited efficacy of chemo-therapy. Studies have shown that drug resistance in these cases is often associated with decreased expression of microRNAs (miRs), small non-coding molecules that play a key role in post-transcriptional regulation of genes by repressing messenger RNA. In several cisplatin-resistant gastric cancer lines, it appears that downregulated miR-503 is correlated with increased expression of IGF-1R and the downstream anti-apoptotic Bcl-2 protein, as these genes appear to be directly regulated by the microRNA. Furthermore, overexpression of miR-503 reduces the activity of these proteins and subsequently re-sensitizes cells to cisplatin-induced apoptosis. miR-1271 seems to play a similar role in gastric cancer cells, restoring cisplatin sensitivity in vitro by repressing IGF-1R, IRS-1, mTOR, and Bcl-2. As such, these studies support a novel approach of using microRNAs to modulate IGF signaling and perhaps even overcome drug resistance.

Colorectal cancer (CRC) continues to be one of the most aggressive malignancies with roughly a third of patients succumbing to the disease within 5 years, despite recent advances leading to earlier diagnosis and treatment. In general, obesity has been associated with poorer outcomes and may underlie drug resistance. One study looked at the in vitro effects on CRC cells of low-dose oxaliplatin, 5-fluorouracil, or irinotecan in combination with obesity-related molecular phenomena, including elevated glucose, insulin, and IGF-1. This was meant to emulate a frequent situation in which obese patients are under-dosed with chemotherapy. Though not always observed with increased insulin or glucose concentrations, the combination of elevated IGF-1 and low-dose chemotherapy consistently increased tumor cell survival. This data provides intriguing insight into how IGF signaling may serve as a link between obesity and development of drug resistance.
One of the mechanisms by which CRC cells are able to develop multidrug resistance is through active efflux by pumps, such as multidrug-resistance-associated protein 2 (MRP-2), which can reduce intracellular drug concentration. IGF signaling has been thought to be involved with this pump activity. In fact, IGF-1R silencing with specific siRNA suppresses MRP-2 in CRC in vitro, thereby increasing intracellular drug concentration of four types of anticancer drugs separately. This effect appears to be mediated via the PI3K/AKT pathway, which causes nuclear translocation of nuclear factor-like 2 (Nrf2) and reduces expression of MRP-2. This study presents yet another mechanism by which resistance can arise, but offers the potential solution that modulating IGF-1R activity can overcome this by maintaining therapeutic drug levels inside target cells.

The role of IGF signaling is also apparent in hepatic and pancreatic cancers resistant to treatment. HA22T, a hepatocellular carcinoma (HCC) cell line resistant to the histone deacetylase inhibitor apicidin, was found to display increased levels of activated IGF-1R, PI3K, AKT, and Bcl-2. Furthermore, the highly proliferative nature of these cells could be attenuated by AKT knockdown. In addition, IGF signaling seems to maintain the self-renewal capacity of cancer stem cells (CSCs) within these tumors. In oxaliplatin-resistant HCC, the stemness of a subpopulation of tumor cells is associated with autocrine signaling of IGF-1, whereas treatment with an IGF-1R inhibitor suppresses CSC-related markers. In pancreatic cancer, IGF-1R knockdown enhances the efficacy of gemcitabine in vitro, likely due to inhibition of the downstream PI3K/AKT and NF-κB activity. K-Ras, a GTPase belonging to the Ras family, is frequently mutated into a constitutively active form in pancreatic ductal adenocarcinoma (PDAC). This mutation also confers resistance to experimental drugs such as rapalog and everolimus, which are mTOR inhibitors, by causing feedback activation of the IGF-1-Ras-ERK pathway. In these cases, K-Ras knockdown blocks IGF-induced ERK signaling and thereby enhances sensitivity to everolimus. Furthermore, targeting IGF signaling may offer another way to overcome drug resistance in tumors identified to have a K-Ras mutation. Overall, there is clear evidence that multiple GI malignancies can be made more responsive to current therapy regimens by better understanding and working to modulate the underlying IGF signaling abnormalities.

Head and neck cancers

Head and neck cancers can have debilitating effects on quality of life, often due to aggressive surgical resection at the time of diagnosis. Despite these efforts, outcomes still remain poor due to the dwindling response of tumors to chemotherapy. IGF signaling remains under considerable investigation for its contributions to this drug resistance. In head and neck squamous cell cancer (HNSCC), similar to lung cancer, EGFR-TKIs have had elicited poor response in tumors, likely due to compensatory pro-survival signaling caused by IGF-1R. In five HNSCC cell lines, IGF-1R activation decreases apoptotic sensitivity to gefitinib in vitro through downstream activation of AKT and ERK. Other studies have demonstrated that IRS-1 may be at the root of this chemoresistance, showing that treatment with gefitinib alters its binding and phosphorylation properties which ultimately requires less IGF ligand for AKT activation. Keeping with these findings, direct IGF-1R inhibition of HNSCC does indeed result in increased response to treatment with EGFR antagonists. Furthermore, various in vitro and
in vivo studies have indicated that IGF signaling blockade can augment the response to histone deacetylase inhibitors, rapamycin, gemcitabine (a nucleoside analog), and even radiation treatment by targeting similar resistance mechanisms.\textsuperscript{105} It is clear that HNSCC represents yet another disease for which IGF modulation may be a suitable adjuvant therapy for overcoming drug resistance.

**Bone and soft tissue tumors**

Unique to most types of cancer, primary bone and soft tissue tumors have a tendency to preferentially affect children and adolescents. This is thought to be due to the underlying mechanisms involved in both normal skeletal growth and the development of these tumors, such as the extensively-studied IGF pathway.\textsuperscript{1} In addition to contributing to the malignant phenotype of bone diseases like osteosarcoma (OS) and Ewing’s sarcoma, IGF signaling now appears to be implicated in tumor response to pharmacologic agents.\textsuperscript{106} For example, IGF-1R inhibition has been shown to inhibit OS proliferation and invasion while increasing sensitivity to both radiation and chemotherapy with docetaxel, cisplatin, or doxorubicin.\textsuperscript{107–110} Furthermore, IGFBP-5 is significantly downregulated in OS, with overexpression of the N- and C-terminal domains of the protein specifically inhibiting tumor growth and invasion, respectively.\textsuperscript{16,17} These effects appear to be mediated through both IGF-dependent and -independent pathways, indicating a potential role for IGFBP-5 in mono- or combination therapy to overcome various mechanisms of drug resistance.\textsuperscript{111}

Rhabdomyosarcoma (RMS) is a soft tissue tumor of muscle that also appears to be influenced by IGF signaling.\textsuperscript{112} In addition to increased activity of IGF-1R, downregulation of IGFBP-2 is associated with resistance of RMS cells to therapy. Furthermore, it has been found that resistance to IGF-1R inhibitors in vivo is actually mediated by decreased IGFBP-2 through IGF-independent activation of PI3K and mTOR.\textsuperscript{113} Another study found that IGF-2 mRNA binding protein 1 (IGF2BP1) is implicated in driving translation of cellular inhibitor of apoptosis 1 (cIAP1), which promotes resistance to tumor necrosis factor-alpha (TNF\(\alpha\)). Inhibiting cIAP1 through IAP antagonists or knockdown of IGF2BP1 promotes sensitivity to TNF\(\alpha\), essentially by preventing proliferative NF-\(\kappa\)B signaling and allowing for caspase-8-mediated cell death.\textsuperscript{114} It seems that studying members of the IGF axis, even those that do not directly mediate IGF-dependent signaling, offers various opportunities for treating tumors that have become resistant to both pre-existing and novel therapeutics.

**Hematologic malignancies**

Affecting patients of all ages, various cancers of the blood and bone marrow are usually not amenable to surgical treatment and unfortunately tend to show erratic response to chemotherapy.\textsuperscript{115,116} Interestingly, though, downstream components of the IGF signaling axis, including PI3K, AKT and mTOR have been heavily implicated in conferring this drug resistance.\textsuperscript{117–120} For example, in multiple myeloma, IGF-1/IGF-1R activity is thought to reduce cell sensitivity to bortezomib, a proteasome inhibitor. Exogenous IGF-1 is shown to amplify this effect, whereas inhibiting IGF-1R using small hairpin RNA increases the apoptotic effect of the drug.\textsuperscript{121} In contrast, other studies have actually shown that IGF-1 enhances the cytotoxic effect of proteasome inhibitors, augmenting the effect of bortezomib.
on both pro-apoptotic and anti-apoptotic protein levels.\textsuperscript{122} These conflicting conclusions may be attributed to varying experimental designs and use of different cell lines/tumors in experiments. Regardless, the role of IGF in myeloma drug resistance is quite intriguing and warrants further investigation to develop novel therapies.

Patients with acute myeloid leukemia (AML) only have a 30–40% survival five years after diagnosis, most often due to development of chemotherapy resistance.\textsuperscript{123} When studying 99 adult patients with AML found to be non-responsive to cytarabine and anthracycline, one group found that high IGFBP-2 mRNA levels are not only associated with, but predictive of, poor response to therapy due to upregulation of genes involved in leukemogenesis.\textsuperscript{124} In addition, IGFBP-7 has been found to sensitize AML to cell death induced by doxorubicin, etoposide, and cytarabine through an IGF-independent mechanism of promoting G2 cell cycle arrest.\textsuperscript{123} However, in acute lymphoblastic leukemia (ALL), an opposite effect is seen as IGFBP-7 has been found to promote resistance to asparginase through interactions with bone marrow stromal cells, even correlating with decreased leukemia-free survival in patients.\textsuperscript{125} Overall, it seems that molecular therapy targeting members of the IGF pathway can one day be developed to enhance response to drugs based on disease-specific mechanisms.

Conclusions and future directions

In conclusion, during a time when cancer treatment has seemingly reached a plateau due to drug resistance, it is critically important to not only understand the underlying mechanisms of this phenomenon but also identify novel therapeutic agents to overcome it. As evidenced by the numerous studies reviewed above (summarized in Table 1), IGF signaling demonstrates significant promise in both of these aims. IGF-mediated effects, as well as IGF-independent signaling by pathway-related molecules, are undoubtedly involved in the response of various tumors to radio- and chemotherapy regimens. Though an important element of normal tissue growth and homeostasis, the IGF pathway appears just as important to cancer disease progression through aberrant signaling. As discussed above, this dysregulation can occur at multiple levels, from crosstalk between IGF and other hormone receptors to constitutive activation of downstream proteins. What is most compelling is that members of this pathway have the ability to promote (or reverse) resistance of various cancer cells to many different classes of drugs (and even radiotherapy) with unique mechanisms of action. Therefore, it can be argued that the IGF axis should be one of the most important foci of research efforts.

Previously, investigators have found the IGF pathway to be implicated in the malignant phenotypes of various neoplasms, focusing their efforts on treating tumors with modulators of this pathway. Many potential drugs, such as IGF-1R inhibitors, have now even made it to clinical trials, but the outcomes of these studies have been largely underwhelming.\textsuperscript{126} Used as monotherapy, these drugs may not prove superior to current standard-of-care chemotherapy, but there exists considerable potential for use of these agents in combination therapy to improve existing treatment regimens. In light of the compelling evidence presented here, future directions seem abundantly clear: understand the effects of IGF signaling modulators in combination with existing drugs in translational and clinical studies.
In addition, more emphasis needs to be placed on studying members of the pathway that exert IGF-independent effects, such as the IGFBPs. We cannot ignore the possibility that such investigations might offer a wide array of therapeutic benefits for drug-resistant tumors. In parallel, researchers should seek to better understand how dysregulation of IGF signaling occurs. This may eventually help clinicians to prevent tumors from becoming not only more aggressive, but also resistant to early therapy. Ultimately, IGF signaling plays a remarkable role in the development and progression of cancer despite therapy, so we must seek to better control its properties if there are to be substantial improvements in patient outcomes in the future.

Acknowledgments

We apologize to the authors whose original work was not cited due to space constraints. The corresponding author’s laboratory was supported in part by a research grant from the National Institutes of Health (AR054381 to HHL). SKD was a recipient of the Pritzker Fellowship and AOA Carolyn L. Kuckein Fellowship. OI was a recipient of the Pritzker Summer Research Program at The University of Chicago.

References

1. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195:127–137. [PubMed: 12767520]
2. Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society. Aug.2002 12:193–197.
3. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res: an official journal of the American Association for Cancer Research. May 1.2010 16:2512–2517.
4. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. Aug.2011 47:R1–R10. [PubMed: 21498522]
5. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. Mar 15.1997 11:701–713. [PubMed: 9087425]
6. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7:85–96. 02//print. [PubMed: 16493415]
7. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol. Sep.2002 64:755–763. [PubMed: 12213567]
8. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (igfbp) superfamily. Endocr Rev. 1999; 20:761–787. [PubMed: 10605625]
9. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. Jan.2007 6:1–12. [PubMed: 17237261]
10. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004; 4:505–518. 07//print. [PubMed: 15229476]
11. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. May 9.1998 351:1393–1396. [PubMed: 9593409]
12. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. Apr 7.1999 91:620–625. [PubMed: 10203281]
13. Roberts CT Jr. IGF-1 and prostate cancer. Novartis Found Symp. 2004; 262:193–199. discussion 199-204, 265-198. [PubMed: 15562830]
14. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer. Aug.2008 3:815–818.
15. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. Dec. 2013 20:R321–R339. [PubMed: 24080445]
16. Su Y, Wagner ER, Luo Q, et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene. Sep 15, 2011 30:3907–3917. [PubMed: 21460855]
17. Luther GA, Lamplot J, Chen X, et al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. Cancer Lett. Aug 9, 2013 336:222–230. [PubMed: 23665505]
18. Chen HX, Sharon E. IGF-1R as an anti-cancer target—trials and tribulations. Chin J Cancer. May 2013 32:242–252. [PubMed: 23601239]
19. Eccleston A, Dhand R. Signalling in cancer. Nature. 2006; 441:423. 05/25/print.
20. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci: a journal and virtual library. 2008; 13:3273–3287.
21. Florea A-M, Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Glob Health Sci. 2013; 2:1–9.
22. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. Feb 1, 2008 68:826–833. [PubMed: 18245484]
23. Zhang Y, Moerkens M, Ramaiiahgari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res: BCR. 2011; 13:R52.
24. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. Jan. 2000 5:95–105. [PubMed: 10791772]
25. Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res: BCR. 2013; 15:R55.
26. Winder T, Giamas G, Wilson PM, et al. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J. Feb. 2014 14:28–34. [PubMed: 23459444]
27. Li C, Harada A, Oh Y. IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78. Cancer Lett. Dec 28, 2012 325:200–206. [PubMed: 22801219]
28. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93:1852–1857. [PubMed: 11752009]
29. Ye XM, Zhu HY, Bai WD, et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC cancer. 2014; 14:134. [PubMed: 24571711]
30. Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. B J Cancer. Apr 10, 2012 106:1367–1373.
31. Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract. 2012; 2012:648965. [PubMed: 22830017]
32. Karamouzis MV, Papavassiliou AG. Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol. Oct. 2012 84:8–17. [PubMed: 22424863]
33. Liu S, Meng X, Chen H, et al. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. May 27, 2014 5:9049–9064. [PubMed: 24979294]
34. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. Jul 1, 2012 72:3372–3380. [PubMed: 22573715]
35. Engelberth SA, Hempel N, Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog. 2014; 19:281–315. [PubMed: 25271436]
36. Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ. Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival? World J Stem Cells. Sep 26.2014 6:441–447. [PubMed: 25258665]

37. Singh RK, Gaikwad SM, Jinager A, Chaudhury S, Maheshwari A, Ray P. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett. Aug 22.2014 354:254–262. [PubMed: 25175649]

38. Koti M, Gooding RJ, Nuin P, et al. Identification of the IGF1/PI3K/NF kappaB/ERK gene-signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013; 13:549. [PubMed: 24237932]

39. Beltran PJ, Calzone FJ, Mitchell P, et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res; an official journal of the American Association for Cancer Research. Jun 1; 2014 20(11):2947–2958.

40. Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PloS One. 2014; 9:e100165. [PubMed: 24932685]

41. SEER Stat Fact Sheets: Prostate Cancer. http://seer.cancer.gov/statfacts/html/prost.html

42. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006; 99:392–401. [PubMed: 16639715]

43. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol: official journal of the American Society of Clinical Oncology. Nov 10.2005 23:8253–8261.

44. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. Feb 15.2004 91:483–490. [PubMed: 14755679]

45. Sharma J, Gray KP, Evan C, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. Feb.2014 74:225–234. [PubMed: 24132762]

46. Gray A, Aronson WJ, Barnard RJ, et al. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. Dec.2011 211:297–304. [PubMed: 21903863]

47. Jones JJ, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A. Nov 15.1993 90:10553–10557. [PubMed: 7504269]

48. Biernacka KM, Uzoh CC, Zeng L, et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. Oct.2013 20:741–751. [PubMed: 23959956]

49. Seki M, Teishima J, Mochizuki H, et al. Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer. Hiroshima J Med Sci. Mar.2013 62:13–19. [PubMed: 23600329]

50. SEER Stat Fact Sheets: Lung and Bronchus Cancer.

51. Zhang W, Lei P, Dong X, Xu C. The new concepts on overcoming drug resistance in lung cancer. Drug Des Devel Ther. 2014; 8:735–744.

52. Peled N, Wynes MW, Ikeda N, et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). Jul.2013 36:277–288. [PubMed: 23619944]

53. Fidler MJ, Basu S, Buckingham L., et al. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. May.2012 32:1705–1710. [PubMed: 22593449]

54. Murakami A, Takahashi F, Nurwidya F, et al. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PloS One. 2014; 9:e86459. [PubMed: 24489728]
55. Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer. Journal international du cancer. Aug 15.2014 135:1002–1006.

56. Vazquez-Martín A, Cufi S, Oliveras-Ferraro C, et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep. 2013; 3:2560. [PubMed: 23994953]

57. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res: an official journal of the American Association for Cancer Research. Feb 1.2006 12:839–844.

58. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res: an official journal of the American Association for Cancer Research. Jul 1.2006 12:3908–3914.

59. Qi HW, Shen Z, Fan LH. Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. Exp Ther Med. Nov.2011 2:1091–1095. [PubMed: 22977626]

60. Jeannot V, Busser B, Brambilla E, et al. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Int J Cancer. Journal international du cancer. Jun 1.2014 134:2560–2571.

61. Kawai M, Breggia AC, DeMambro VE, et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. Apr 22.2011 286:14670–14680. [PubMed: 21372140]

62. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. Apr.2008 49:615–619. [PubMed: 18398720]

63. Lu H, Wang L, Gao W, et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. Dec.2013 12:2864–2873. [PubMed: 24130049]

64. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. Jul.2008 118:2609–2619. [PubMed: 18568074]

65. Choi YJ, Park GM, Rho JK, et al. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors. PloS One. 2013; 8:e81393. [PubMed: 24399922]

66. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, Lund PK. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol Gastrointest Liver Physiol. Mar.2000 278:G447–G457. [PubMed: 10712265]

67. Cortes-Sempere M, de Miguel MP, Pernia O, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFR/Akt pathway in non-small cell lung cancer. Oncogene. Mar 7.2013 32:1274–1283. [PubMed: 22543588]

68. Sun Y, Zheng S, Torossian A, et al. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys. Mar 1.2012 82:e563–572. [PubMed: 22197230]

69. Suzuki H, Igarashi S, Nojima M, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis. Mar.2010 31:342–349. [PubMed: 19638426]

70. Okamura J, Huang Y, Moon D, Brait M, Chang X, Kim MS. Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer. Cancer Biol Ther. Feb 1.2012 13:148–155. [PubMed: 22277373]

71. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012; 205:613–621. 12//. [PubMed: 23238284]

72. Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer. Jan.2014 33:1–3. [PubMed: 24384235]
73. Osaka S, Sampetrean O, Shimizu T, et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem cells (Dayton, Ohio). Apr.2013 31:627–640.

74. Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J Cell Physiol. Apr.2011 226:1118–1127. [PubMed: 20857406]

75. Li C, Zhou C, Wang S, et al. Sensitization of glioma cells to tamoxifen-induced apoptosis by PI3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PloS One. 2011; 6:e27053. [PubMed: 22046442]

76. Chen MY, Clark AJ, Chan DC, et al. Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol. May.2011 103:87–102. [PubMed: 20820871]

77. Fuller GN, Rhee CH, Hess KR, et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. Sep 1.1999 59:4228–4232. [PubMed: 10485462]

78. Han S, Li Z, Master LM, Master ZW, Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. B J Cancer. Aug 5.2014 111:1400–1409.

79. Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers. 2013; 5:48–63. [PubMed: 24216698]

80. Bochatay L, Girardin M, Bichard P, Frossard JL. Pancreatic cancer in 2014: screening and epidemiology. Revue medicale suisse. Sep 3.2014 10:1582–1585. [PubMed: 25276995]

81. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. Mar-Apr;2011 61:69–90. [PubMed: 21296855]

82. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007; 8:93–103. 02//print. [PubMed: 17230196]

83. Cui YH, Xiao L, Rao JN, et al. miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell. Jan.2012 23:151–162. [PubMed: 22072795]

84. Wang T, Ge G, Ding Y, et al. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J. 2014; 127:2357–2362. [PubMed: 24931256]

85. Yang M, Shan X, Zhou X, et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014; 14:884–891. [PubMed: 24875127]

86. SEER Stat Fact Sheets: Colon and Rectum Cancer. http://seer.cancer.gov/statfacts/html/colorect.html

87. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer. Oct.2012 19:F27–F45. [PubMed: 22593429]

88. Volkova E, Robinson BA, Willis J, Currie MJ, Dachs GU. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett. Feb.2014 7:311–320. [PubMed: 24396438]

89. Lyman GH, Sparreboom A. Chemotherapy dosing in over-weight and obese patients with cancer. Nat Rev Clin Oncol. 2013; 10:451–459. 08//print. [PubMed: 23856744]

90. Haimer A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. Feb.2004 5:21–53. [PubMed: 14965249]

91. Shen K, Cui D, Sun L, Lu Y, Han M, Liu J. Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. Jun.2012 113:2086–2097. [PubMed: 22275271]

92. Hsu HH, Cheng LH, Ho TJ, et al. Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine. Jan.2014 35:303–313.

93. Shan J, Shen J, Liu L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (Baltimore, Md.). Sep. 2012 56:1004–1014.
94. Bu Y, Jia QA, Ren ZG, et al. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PloS One. 2014; 9:e89686. [PubMed: 24632571]

95. Tian X, Hao K, Qin C, Xie K, Xie X, Yang Y. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci. Sep.2013 58:2705–2712. [PubMed: 23589145]

96. Morris, JPt; Wang, SC.; Hebrok, M.; KRAS. Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. Oct.2010 10:683–695. [PubMed: 20814421]

97. Wei F, Liu Y, Bellail AC, et al. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Lett. Sep 1.2012 322:58–69. [PubMed: 22342683]

98. Dropkin MJ. Body image and quality of life after head and neck cancer surgery. Cancer Pract. Nov-Dec;1999 7:309–313. [PubMed: 10732529]

99. So WKW, Chan RJ, Chan DNS, et al. Quality-of-life among head and neck cancer survivors at one year after treatment – a systematic review. Eur J Cancer. 48(15):2391–2408. [PubMed: 22579456]

100. Bier H. Chemotherapeutic drug resistance in the management of head and neck cancer. Eur Arch Otorhinolaryngol: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 1993; 250:200–208.

101. Szafarowski T, Szczepanski MJ. Cancer stem cells in head and neck squamous cell carcinoma. Otolaryngologia polska. The Polish Otolaryngology. May-Jun;2014 68:105–111.

102. Jameson MJ, Beckler AD, Taniguchi LE, et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther. Nov 1.2011 10:2124–2134. [PubMed: 21878657]

103. Knowlden J, Jones H, Barrow D, Gee JW, Nicholson R, Hutcheson I. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat. 2008; 111:79–91. /09/01 2008. [PubMed: 17902048]

104. Chung CH, Pohlmann PR, Rothenberg ML, et al. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck. 2011; 33:1804–1808. [PubMed: 20652976]

105. Limesand KH, Chibley AM, Fribley A. Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res: official journal of the Growth Hormone Research Society and the International IGF Research Society. Oct.2013 23:135–140.

106. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist. Jan 1.2009 14:83–91. [PubMed: 19126579]

107. Wang YH, Xiong J, Wang SF, et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem. Aug.2010 341:225–233. [PubMed: 20376336]

108. Wang YH, Wang ZX, Qiu Y, et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem. Jul.2009 327:257–266. [PubMed: 19229591]

109. Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest. Oct.2011 29:521–532. [PubMed: 21843050]

110. Duan Z, Choy E, Harmon D, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. Aug 1.2009 8:2122–2130. [PubMed: 19638450]

111. Tripathi G, Salih DA, Drozd AC, Cosgrove RA, Cobb LJ, Pell JM. IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo. FASEB J: official publication of the Federation of American Societies for Experimental Biology. Aug.2009 23:2616–2626.

112. de Souza RR, Oliveira ID, del Giudice Paniago M, et al. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas. Growth Horm IGF Res: official journal of
113. Kang Z, Yu Y, Zhu YJ, et al. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene. Dec 2013 ;1–9.

114. Faye MD, Beug ST, Graber TE, et al. IGFBP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. Apr 2014;1–10.

115. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. The journal of medical investigation. JMI. Aug.2003 50:126–135. [PubMed: 13678381]

116. Lichtman MA. Battling the hematological malignancies: the 200 years’ War. Oncologist. Feb 2008 13:126–138. [PubMed: 18305057]

117. Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs. Oct 2012 14:299–316. [PubMed: 22845486]

118. Bartalucci N, Tozzi L, Bogani C, et al. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. Nov 2013 17:1385–1396. [PubMed: 24237791]

119. Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther. Sep 2014 :1–8. (in press).

120. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/m-TOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108. [PubMed: 24904824]

121. Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. Oct 2012 120:3260–3270. [PubMed: 22932796]

122. Tagoug I, Jordheim LP, Herveau S, et al. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clin Cancer Res: an official journal of the American Association for Cancer Research. Jul 2013 19:3556–3566.

123. Verhagen HJ, de Leeuw DC, Roemer MG, et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dis. 2014;5:e1300. [PubMed: 24967962]

124. Kuhnl A, Kaiser M, Neumann M, et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. Dec 2011 35:1585–1590. [PubMed: 21899885]

125. Laranjeira AB, de Vasconcellos JF, Sodek L, et al. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase. Leukemia. May 2012 26:1001–1011. [PubMed: 22005787]

126. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. Oct 2014 40:1096–1105. [PubMed: 25123819]
Figure 1.
Schematic of IGF signaling and major downstream effects. Activation of IGF-1R can result in signaling via two pathways: PI3K/AKT and Ras/MAPK. PI3K/AKT results in decreased apoptosis, increased protein synthesis, and increased glucose metabolism, among various other effects not represented here. Ras/MAPK contains an elaborate kinase cascade that ultimately leads to increased cellular proliferation by promoting the activity of transcription factors, such as ELK1. The activity of IGF ligands is modulated by IGFBPs through direct binding in the extracellular space. IGFBPs also exert several IGF-independent effects via direct interaction with cell membrane-bound proteins, such as integrins.
### Table 1

Summary of IGF pathway members and their implications in promoting resistance or sensitivity to therapy among various human cancers.

| IGF pathway member | Observed or experimental change | Confers resistance or increases sensitivity? | Affected cancer: Drug/Treatment |
|--------------------|---------------------------------|---------------------------------------------|---------------------------------|
| IGF-1R             | ↑                               | Resistance                                  | Breast ER+: Tamoxifen<sup>22</sup> |
|                    |                                 |                                             | Breast HER2+: Trastuzumab<sup>28</sup> |
|                    |                                 |                                             | Gastric: Cisplatin<sup>54</sup> |
|                    |                                 |                                             | Glioma: Radiation<sup>71</sup>, Temozolamide<sup>74</sup> |
|                    |                                 |                                             | Hepatocellular: Apicidin<sup>92</sup> |
|                    |                                 |                                             | HNSCC: Gefitinib<sup>102</sup> |
|                    |                                 |                                             | NSCLC: Gefitinib<sup>52</sup>, Erlotinib<sup>55</sup> |
|                    |                                 |                                             | Osteosarcoma: Radiation<sup>108</sup>, Docetaxel, Cisplatin<sup>107</sup> |
|                    |                                 |                                             | Doxorubicin<sup>109,110</sup> |
|                    |                                 |                                             | Ovarian: Cisplatin ± taxol<sup>17</sup> |
|                    |                                 |                                             | Prostate: Androgen deprivation therapy<sup>42</sup> |
|                    | ↓                               | Sensitivity                                 | Colorectal: Multiple<sup>91</sup> |
|                    |                                 |                                             | Gastric: Cisplatin<sup>54,55</sup> |
|                    |                                 |                                             | Glioma: Radiation<sup>75</sup> |
|                    |                                 |                                             | Hepatocellular: Oxaliplatin<sup>94</sup> |
|                    |                                 |                                             | HNSCC: Methotrexate, Cetuximab, histone deacetylase inhibitors, Rapamycin, Gemcitabine, Radiation<sup>105</sup> |
|                    |                                 |                                             | Multiple myeloma: Bortezomib<sup>121</sup> |
|                    |                                 |                                             | NSCLC: Gefitinib<sup>54</sup> |
|                    |                                 |                                             | Ovarian: Platinum-based drugs<sup>39</sup> |
|                    |                                 |                                             | Pancreatic: Gemcitabine<sup>95</sup> |
|                    |                                 |                                             | Prostate: Androgen deprivation therapy<sup>42</sup> |
| IGF-1              | ↑                               | Resistance                                  | Colorectal: Oxaliplatin, 5-Fluorouracil, Irinotecan<sup>88</sup> |
|                    |                                 |                                             | Glioma: Tamoxifen<sup>75</sup> |
|                    |                                 |                                             | Hepatocellular: Oxaliplatin<sup>94</sup> |
|                    |                                 |                                             | Multiple myeloma: Bortezomib<sup>121</sup> |
|                    |                                 |                                             | Pancreatic: Everolimus<sup>97</sup> |
|                    | ↑                               | Sensitivity                                 | Multiple myeloma: Bortezomib<sup>122</sup> |
| IGF-2              | ↑                               | Resistance                                  | Ovarian: Platinum-based drugs<sup>39</sup> |
|                    | ↓                               | Sensitivity                                 | Ovarian: Taxol<sup>80</sup> |
| PI3K/AKT           | ↑                               | Resistance                                  | NSCLC: Gefitinib<sup>90</sup> |
|                    | ↓                               | Sensitivity                                 | Glioma: Tamoxifen<sup>75</sup> |
|                    |                                 |                                             | Hepatocellular: Apicidin<sup>92</sup> |
|                    |                                 |                                             | NSCLC: Gefitinib<sup>90</sup> |
| Ras/ERK            | ↑                               | Resistance                                  | Pancreatic: Everolimus<sup>97</sup> |
|                    | ↓                               | Sensitivity                                 | Pancreatic: Everolimus<sup>97</sup> |
| IGF pathway member | Observed or experimental change | Confers resistance or increases sensitivity? | Affected cancer: Drug/Treatment |
|--------------------|---------------------------------|--------------------------------------------|-------------------------------|
| IGFBP-1            | ↑                               | Resistance                                  | Prostate: Androgen deprivation therapy<sup>45</sup> |
|                    | ↓                               | Sensitivity                                  | Prostate: Androgen deprivation therapy<sup>46,47</sup> |
| IGFBP-2            | ↑                               | Resistance                                  | AML: Cytarabine, Anthracycline<sup>124</sup> |
|                    |                                  |                                            | Glioma: Temozolamide<sup>78</sup> |
|                    |                                  |                                            | NSCLC: Dasatinib<sup>62,63</sup> |
|                    |                                  |                                            | Prostate: Docetaxel<sup>48</sup> |
|                    | ↓                               | Sensitivity                                  | NSCLC: Dasatinib<sup>63</sup> |
|                    |                                  |                                            | Prostate: Docetaxel<sup>48</sup> |
|                    | ↓                               | Resistance                                  | RMS: IGF-1R antibody<sup>113</sup> |
| IGFBP-3            | ↓                               | Resistance                                  | NSCLC: Gefitinib, Erlotinib, Cisplatin<sup>67</sup> |
|                    |                                  | Sensitivity                                  | Breast ER+: Fulvestrant<sup>27</sup> |
|                    | ↑                               | NSCLC: Cisplatin<sup>66</sup>               |                               |
| IGFBP-7            | ↓                               | Resistance                                  | NSCLC: Cisplatin<sup>70</sup> |
|                    | ↑                               | Sensitivity                                  | AML: Doxorubicin, Etoposide, Cytarabine<sup>121</sup> |
|                    |                                  |                                            | NSCLC: Cisplatin<sup>70</sup> |
|                    | ↑                               | Resistance                                  | ALL: Asparginase<sup>125</sup> |
| IGFBP-rP1          | ↑                               | Sensitivity                                  | Prostate: Docetaxel, Radiation<sup>49</sup> |
| IGF2BP1            | ↓                               | Resistance                                  | RMS: TNFζ<sup>114</sup> |

Abbreviations – ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ER+: estrogen receptor positive; HNSCC: Head and neck squamous cell cancer; IGF2BP1: insulin-like growth factor 2 mRNA binding protein 1; IGFBP-rP1: insulin-like growth binding protein related peptide 1; NSCLC: Non-small cell lung cancer; RMS: rhabdomyosarcoma

The upward arrows represent either upregulation, overexpression, or otherwise increased activity of the specific IGF pathway member as observed or experimentally changed in the study. The downward arrows represent either downregulation, underexpression, or otherwise decreased activity of the specified IGF pathway member.